semaglutide compound stopping Compounded' weight-loss drugs are a growing problem for state regulators • Stateline semaglutide compound stopping Is compound
Description
Its still being tested in Phase 3 clinical trials, which are the large studies researchers run before asking regulators to approve a new drug
However, noticeable weight loss may not begin until individuals reach their maintenance dose
As of March 31, 2024, the FDA received 442 adverse event reports related to compounded semaglutide, including 319 serious cases, 99 hospitalizations, and 7 deaths
This approach almost always results in severe nausea, vomiting, and an overall terrible experience that makes the person question whether switching was a good idea at all
GLP-1 quietly swapped that constraint for another
